HY2Care Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 10
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $4.15M
Latest Deal Amount
  • Investors
  • 5

HY2Care General Information

Description

Manufacturer of an injectable hydrogel designed to repair cartilage defects. The company's hydrogel is a two-component injectable and bioresorbable which is made by composed of a mixture of natural polymer conjugates that cross-link in a mild enzymatic reaction, enabling people to get access to a medical product which aims at functional repair of cartilage defects in the knee.

Contact Information

Website
www.hy2care.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Primary Office
  • ZH143
  • Drienerlolaan 5
  • 7522 NB Enschede
  • Netherlands
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

HY2Care Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) 30-Apr-2019 $4.15M 00.000 Completed Generating Revenue
3. Grant 04-Aug-2016 000.00 000.00 Completed Generating Revenue
2. Accelerator/Incubator 13-Apr-2015 $16.2K $16.2K Completed Generating Revenue
1. Grant Completed Startup
To view HY2Care’s complete valuation and funding history, request access »

HY2Care Patents

HY2Care Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3088978-A1 Porous affinity hydrogel particles for reducing the bioavailability of selected biological molecules Pending 18-Jan-2018 000000000
JP-2021511431-A Porosity-affinity hydrogel particles to reduce bioavailability of selected biomolecules Pending 18-Jan-2018 000000000
EP-3740525-A1 Porous affinity hydrogel particles for reducing the bioavailability of selected biological molecules Pending 18-Jan-2018 000000000
US-20200347125-A1 Porous affinity hydrogel particles for reducing the bioavailability of selected biological molecules Pending 18-Jan-2018 000000000
US-20120276069-A1 Hydrogels based on polymers of dextran tyramine and tyramine conjugates of natural polymers Granted 11-Nov-2009 A61K47/54 00
To view HY2Care’s complete patent history, request access »

HY2Care Executive Team (5)

Name Title Board Seat Contact Info
Leo Smit Chief Executive Officer
Ron Coenen Chief Financial Officer
Sanna Severins Chief Operating Officer
Chris Cardinaels Co-Founder
Marcel Karperien Chief Scientific Officer & Co-Founder
To view HY2Care’s complete executive team members history, request access »

HY2Care Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HY2Care Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Brightlands Venture Partners Venture Capital Minority 000 0000 000000 0
ReumaNederland Other Minority 000 0000 000000 0
Horizon 2020 Government 000 0000 000000 0
Startupbootcamp Accelerator/Incubator Minority 000 0000 000000 0
Lifesciences@work Other 000 0000 000000 0
To view HY2Care’s complete investors history, request access »